RNAAtrium Therapeutics Inc.
$12.30
$0.08
(0.66%)
Closed $12.30
$0.24
(1.95%)
After Hours
Reported EarningsMay 14
Mkt Cap$209.03M
Vol88,791.00
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome PR Newswire SAN DIEGO, July 14, 2026...
PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, June 23, 2026 SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the...
PR Newswire
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Atrium Therapeutics Reports First Quarter 2026 Financial Results Atrium Therapeutics Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026...
PR Newswire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers...
PR Newswire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, April...
PR Newswire
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies Atrium Therapeutics Launches with Approximately $270 Million to Advance...
PR Newswire
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Avidity Biosciences Announces Multiple Upcoming...
PR Newswire
Promising Medical Stocks To Follow Today - February 26th
Eli Lilly and Company, UnitedHealth Group, Arcellx, Avidity Biosciences, and Novo Nordisk A/S are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...
MarketBeat
Promising Pharmaceutical Stocks To Follow Now - February 26th
Eli Lilly and Company, Avidity Biosciences, Novo Nordisk A/S, AbbVie, Gilead Sciences, Abbott Laboratories, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...
MarketBeat
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results
Avidity Biosciences (NASDAQ:RNA - Get Free Report) released its earnings results on Monday. The biotechnology company reported ($1.59) earnings per share for the quarter, missing analysts' consensus...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest RNA News
ViewAtrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
PR Newswire
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Atrium Therapeutics Reports First Quarter 2026 Financial Results
PR Newswire
Advertisement|Remove ads.